Having trouble accessing articles? Reset your cache.

Vivo-led $105M round to spur development of ALX’s CD47

Vivo thinks ALX’s CD47-targeted cancer therapy could be best in class thanks to its safety profile

Encouraged by safety data for ALX’s CD47-targeted cancer therapy, Vivo Capital led the biotech’s $105 million series C Wednesday to fuel its clinical catch-up to its most advanced competitor.

Other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners and HBM Healthcare Investments participated in the untranched financing,

Read the full 563 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers